To the Editor In their article published in the December 2018 issue of JAMA Psychiatry entitled “Association of Autism Spectrum Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems,”1 Janecka et al made several statements and conclusions that do not appear warranted. The problem stems from an inappropriate grouping of agents thought to affect the serotonin transporter. Specifically, the decongestant pseudoephedrine was included in the group along with known selective and nonselective reuptake inhibitors. The inclusion of pseudoephedrine is clearly in error as pseudoephedrine has been shown to have very little or no affinity for the transporter.2,3
Anderson GM. Autism Risk and Serotonin Reuptake Inhibitors. JAMA Psychiatry. 2019;76(5):547–548. doi:10.1001/jamapsychiatry.2019.0073
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: